Dafinchi AI

IONS

Healthcare

Ionis reported revenue of $452 million in Q2 2025, a twofold increase year-over-year, and $584 million for the first six months, up nearly 70% versus prior year.
Non-GAAP net income was $154 million for the quarter.
Operating expenses increased 8% year-over-year, with sales and marketing expenses rising due to Tryngolza launch and Donidalorsen preparations, while R&D expenses decreased as late-stage studies concluded.
R&D collaboration revenue included a $280 million upfront payment for the sapablursen license, nearly 100% of which dropped to the bottom line.
Royalty revenues increased approximately 10% to $70 million, driven by SPINRAZA and Wainua contributions.
Sales and marketing expenses included minority portion of Wainua's sales and marketing costs.
Tryngolza generated $19 million in net product sales in Q2, a threefold increase quarter-over-quarter.

INSM

Healthcare

ARIKAYCE delivered double-digit year-over-year revenue growth globally, with the highest quarterly revenue ever achieved in the United States.
Cash balance increased to approximately $1.9 billion following a $823 million net proceeds equity offering.
Cost of product revenues was $28.1 million or 26.1% of revenues, slightly higher due to increased international sales proportion.
Europe sales grew 48%, primarily due to strong demand in Germany, Switzerland, and Austria.
Full year 2025 ARIKAYCE net revenue guidance remains $405 million to $425 million.
Japan sales grew 45% driven by new targeting strategies and improved patient experience.
Operating expenses increased due to investments in commercial readiness for brensocatib and pipeline funding.

GILD

Healthcare

Cell therapy sales declined 7% year-over-year to $485 million, impacted by competitive headwinds but showed 5% sequential growth.
Gilead reported base business sales of $6.9 billion, up 4% year-over-year, driven by strong growth in Biktarvy, Descovy, Livdelzi, and Trodelvy.
HIV sales grew 7% year-over-year to $5.1 billion, with Biktarvy up 9% and Descovy up 35%, marking Descovy's strongest quarter ever.
Non-GAAP diluted EPS was $2.01 for the quarter, with operating margin at 46% (47% excluding acquired IPR&D).
Total product sales were $7.1 billion, a 2% increase year-over-year, with Veklury sales declining 44% due to fewer COVID-19 hospitalizations.
Trodelvy sales increased 14% year-over-year to $364 million, supported by metastatic breast cancer indications.

Earnings Feed